331 related articles for article (PubMed ID: 16311119)
21. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
22. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
24. RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous system.
Inda MM; Castresana JS
Neuropathology; 2007 Aug; 27(4):341-6. PubMed ID: 17899687
[TBL] [Abstract][Full Text] [Related]
25. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
26. No evidence for mutations or altered expression of the Suppressor of Fused gene (SUFU) in primitive neuroectodermal tumours.
Koch A; Waha A; Hartmann W; Milde U; Goodyer CG; Sörensen N; Berthold F; Digon-Söntgerath B; Krätzschmar J; Wiestler OD; Pietsch T
Neuropathol Appl Neurobiol; 2004 Oct; 30(5):532-9. PubMed ID: 15488029
[TBL] [Abstract][Full Text] [Related]
27. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
28. Frequent hypermethylation of the RASSF1A gene in prostate cancer.
Liu L; Yoon JH; Dammann R; Pfeifer GP
Oncogene; 2002 Oct; 21(44):6835-40. PubMed ID: 12360410
[TBL] [Abstract][Full Text] [Related]
29. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
[TBL] [Abstract][Full Text] [Related]
30. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
[TBL] [Abstract][Full Text] [Related]
31. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer.
Choi CH; Lee KM; Choi JJ; Kim TJ; Kim WY; Lee JW; Lee SJ; Lee JH; Bae DS; Kim BG
Cancer Lett; 2007 Sep; 255(1):26-33. PubMed ID: 17467893
[TBL] [Abstract][Full Text] [Related]
32. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
34. Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation.
Hussain A; Gutiérrez MI; Timson G; Siraj AK; Deambrogi C; Al-Rasheed M; Gaidano G; Magrath I; Bhatia K
Genes Chromosomes Cancer; 2004 Dec; 41(4):321-9. PubMed ID: 15384174
[TBL] [Abstract][Full Text] [Related]
35. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma.
Murray PG; Qiu GH; Fu L; Waites ER; Srivastava G; Heys D; Agathanggelou A; Latif F; Grundy RG; Mann JR; Starczynski J; Crocker J; Parkes SE; Ambinder RF; Young LS; Tao Q
Oncogene; 2004 Feb; 23(6):1326-31. PubMed ID: 14961078
[TBL] [Abstract][Full Text] [Related]
36. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
37. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
38. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.
Chen H; Suzuki M; Nakamura Y; Ohira M; Ando S; Iida T; Nakajima T; Nakagawara A; Kimura H
Oncol Rep; 2006 May; 15(5):1281-5. PubMed ID: 16596198
[TBL] [Abstract][Full Text] [Related]
39. Combined BubR1 protein down-regulation and RASSF1A hypermethylation in Wilms tumors with diverse cytogenetic changes.
Haruta M; Matsumoto Y; Izumi H; Watanabe N; Fukuzawa M; Matsuura S; Kaneko Y
Mol Carcinog; 2008 Sep; 47(9):660-6. PubMed ID: 18286482
[TBL] [Abstract][Full Text] [Related]
40. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
Dammann R; Yang G; Pfeifer GP
Cancer Res; 2001 Apr; 61(7):3105-9. PubMed ID: 11306494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]